What‌ Happened?

Field trials for a ‍cattle vaccine against bovine tuberculosis (bTB) and a companion ​diagnostic skin‍ test have entered thier next phase, as announced by the ⁤Animal and​ Plant Health Agency (APHA) on October 21, 2024.These trials, conducted on commercial farms ⁢in England and Wales, represent a crucial step towards a potential ⁣vaccine ⁣deployable⁤ within the next few ‍years.

The Challenge of‍ Bovine Tuberculosis

Bovine tuberculosis is a persistent and costly animal health issue globally. In England alone,bTB costs approximately £100 million ⁤annually,with an additional⁢ estimated‌ £50 million impact on the wider farming industry​ ‍ (Gov.UK,2023). During⁢ the ⁤2023/24 period, ‌over⁣ 60,000 cattle in England and Wales‌ were culled in ⁤efforts ⁣to control ⁣the disease (Gov.UK, 2023). Current control measures rely heavily on stringent testing and the removal of infected animals, a process ​that ​is both economically damaging and emotionally distressing for farmers.

The current testing regime ‍utilizes the Single ⁣Intradermal Comparative⁤ Tuberculin (SICCT) test. Though,⁢ this test ‌cannot differentiate between vaccinated⁣ and infected⁣ animals, hindering the widespread adoption of⁤ a ​vaccination​ strategy. This is where the DIVA (Differentiating Infected from Vaccinated Animals) skin test becomes critical.

CattleBCG and the DIVA Skin Test: A Combined ‌Approach

The⁤ CattleBCG vaccine, ​developed by APHA, ‍aims to protect cattle ⁤from bTB infection and reduce transmission.Crucially,it is indeed being used in conjunction with the companion DIVA skin test.The DIVA test allows farmers ⁤and veterinarians to‌ distinguish⁢ between animals that have been vaccinated and those‍ that are genuinely infected ⁢with bTB. ⁢This differentiation is essential ⁢for​ maintaining confidence ‍in the⁣ testing program and avoiding ⁤unnecessary culling.

The DIVA⁢ test works by using a different tuberculin ​protein for vaccinated animals‍ than for those ⁤possibly infected. ⁣ A positive reaction to one tuberculin⁢ indicates vaccination, while​ a positive ‌reaction to the other suggests infection.

phase 3 Trials: Details and timeline

The current Phase 3 field trials are taking place on⁢ at least ⁤10 ⁢commercial livestock farms across the Low-Risk Area in ​England and ⁣the Low TB Area in Wales. ‌ Approximately 750 ⁢animals ⁣are enrolled in the study, with all⁣ receiving ⁤both the CattleBCG vaccine and the DIVA skin test. The trials are scheduled for completion in 2026.

The ​data collected‍ during these trials will ‍be used to support​ applications for ⁢GB Marketing Authorisations‍ for both the CattleBCG vaccine and the companion DIVA skin test.Triumphant authorisation would pave ​the way for wider deployment of